ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in- class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon "Spyros" Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and pres ...

ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in- class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon "Spyros" Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and pres ...

BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210's emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments. Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210's registrational program in PTSD by end of the se ...

ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY. Spyros Papapetropoulos, M.D ...

BNC210在创伤后应激障碍（PTSD）中的表现 - BNC210在创伤后应激障碍（PTSD）中显示出降低总症状严重程度和多个症状群的积极2b期数据[1] - 公司正在积极进行战略合作伙伴关系讨论，评估在PTSD中继续临床开发计划的选项[3] - Bionomics在2023年完成了强劲的发展，包括在PTSD的ATTUNE试验和与FDA的EoP2会议中取得积极结果[4] BNC210在社交焦虑障碍（SAD）中的表现 - BNC210在社交焦虑障碍（SAD）中取得了积极的2b期终点会议结果，为第3期启动提供了支持[2] - 公司正在积极进行战略合作伙伴关系讨论，评估在SAD中继续临床开发计划的选项[3]

| --- | --- | |--------------------------------------|-------| | | | | TO IMPROVE THE | | | LIVES OF | | | PATIENTS WITH SERIOUS CNS DISORDERS | | | Corporate Presentation | | | ASX: BNO | | | Nasdaq: BNOX | | | April 2022 | | SAFE HARBOR STATEMENT 2 Factors Affecting Future Performance This presentation may contain "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective e ...